WRN protects against topo I but not topo II inhibitors by preventing DNA break formationCHRISTMANN, Markus; TOMICIC, Maja T; GESTRICH, Christopher et al.DNA repair. 2008, Vol 7, Num 12, pp 1999-2009, issn 1568-7864, 11 p.Article

Mechanisms of resistance to topoisomerase I-targeting drugsRASHEED, Zeshaan A; RUBIN, Eric H.Oncogene (Basingstoke). 2003, Vol 22, Num 47, pp 7296-7304, issn 0950-9232, 9 p.Article

Topotecan-induced bronchiolitisEDGERTON, Colin C; GILMAN, Matthew; ROTH, Bernard J et al.Southern medical journal (Birmingham). 2004, Vol 97, Num 7, pp 699-701, issn 0038-4348, 3 p.Article

Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approachLUPI, Monica; MATERA, Giada; BRANDUARDI, Davide et al.Cancer research (Baltimore). 2004, Vol 64, Num 8, pp 2825-2832, issn 0008-5472, 8 p.Article

A phase I study of Topotecan, as a radiosensitizer, for thoracic malignanciesFOROUZANNIA, Afshin; SCHILLER, Joan; BERLIN, Jordan et al.Lung cancer. 2004, Vol 44, Num 1, pp 111-119, issn 0169-5002, 9 p.Article

Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecanFISCHER, L; THIEL, E; KLASEN, H. A et al.Neurology. 2004, Vol 62, Num 10, pp 1885-1887, issn 0028-3878, 3 p.Article

Regression of Recurrent Malignant Gliomas With Convection-Enhanced Delivery of TopotecanBRUCE, Jeffrey N; FINE, Robert L; BAGIELLA, Emilia et al.Neurosurgery. 2011, Vol 69, Num 6, pp 1272-1279, issn 0148-396X, 8 p.Article

Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in childrenTURNER, P. Kellie; IACONO, Lisa C; PANETTA, John C et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 4, pp 475-482, issn 0344-5704, 8 p.Article

Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenograftsPINEL, Sophie; CHASTAGNER, Pascal; MERLIN, Jean-Louis et al.Journal of neuro-oncology. 2006, Vol 76, Num 1, pp 31-38, issn 0167-594X, 8 p.Article

Influence of the cisplatin hydration schedule on topotecan pharmacokineticsGELDERBLOM, H; LOOS, W. J; SPARREBOOM, A et al.European journal of cancer (1990). 2003, Vol 39, Num 11, pp 1542-1546, issn 0959-8049, 5 p.Article

In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant gliomaCIUSANI, Emilio; CROCI, Danilo; GELATI, Maurizio et al.Journal of neuro-oncology. 2005, Vol 71, Num 1, pp 19-25, issn 0167-594X, 7 p.Article

A novel method to load topotecan into liposomes driven by a transmembrane NH₄EDTA gradientYUEHUI YANG; YANLING MA; SHAONING WANG et al.European journal of pharmaceutics and biopharmaceutics. 2012, Vol 80, Num 2, pp 332-339, issn 0939-6411, 8 p.Article

Treatment options for endometrial cancer: experience with topotecanHOLLOWAY, Robert W.Gynecologic oncology (Print). 2003, Vol 90, Num 3, pp S28-S33, issn 0090-8258, 2Conference Paper

Workshop: options for therapy in ovarian cancerHERZOG, Thomas J; HOLLOWAY, Robert W; STUART, Gavin C. E et al.Gynecologic oncology (Print). 2003, Vol 90, Num 3, pp S45-S50, issn 0090-8258, 2Conference Paper

Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantroneYANG, Chih-Hsin; CHEN, Yao-Chang; KUO, Min-Liang et al.Anticancer research. 2003, Vol 23, Num 3B, pp 2519-2523, issn 0250-7005, 5 p.Article

Prospective trial on topotecan salvage therapy in primary CNS lymphomaFISCHER, L; THIEL, E; KLASEN, H.-A et al.Annals of oncology. 2006, Vol 17, Num 7, pp 1141-1145, issn 0923-7534, 5 p.Article

Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adultsGROSS, Markus W; ALTSCHER, Riglef; BRANDTNER, Michael et al.Clinical neurology and neurosurgery. 2005, Vol 107, Num 3, pp 207-213, issn 0303-8467, 7 p.Article

Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancerRAMALINGAM, S; BELANI, C. P; DAY, R et al.Annals of oncology. 2004, Vol 15, Num 2, pp 247-251, issn 0923-7534, 5 p.Article

Optimal sequencing in the treatment of recurrent ovarian cancerSPRIGGS, David.Gynecologic oncology (Print). 2003, Vol 90, Num 3, pp S39-S44, issn 0090-8258, 2Conference Paper

The role of topotecan in the treatment of advanced cervical cancerFIORICA, James V.Gynecologic oncology (Print). 2003, Vol 90, Num 3, pp S16-S21, issn 0090-8258, 2Conference Paper

Weekly topotecan in the management of ovarian cancerMORRIS, Robert T.Gynecologic oncology (Print). 2003, Vol 90, Num 3, pp S34-S38, issn 0090-8258, 2Conference Paper

A Semi-physiological-Based Pharmacokinetic/Pharmacodynamic Model to Describe the Effects of Topotecan on B-Lymphocyte Lineage CellsVELEZ DE MENDIZABAL, Nieves; MARTINEZ-FORERO, Iván; GARRIDO, María J et al.Pharmaceutical research. 2010, Vol 27, Num 3, pp 431-441, issn 0724-8741, 11 p.Article

Development of a highly stable and targetable nanoliposomal formulation of topotecanDRUMMOND, Daryl C; NOBLE, Charles O; BENZ, Christopher C et al.Journal of controlled release. 2010, Vol 141, Num 1, pp 13-21, issn 0168-3659, 9 p.Article

Topotecan-carboplatin-etoposide combination as 1 st line treatment in patients with small cell lung cancerZAROGOULIDIS, K; MYLONAKI, E; KAKAVELAS, P et al.Lung cancer. 2009, Vol 66, Num 2, pp 226-230, issn 0169-5002, 5 p.Article

Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenograftsBALSARI, A; TORTORETO, M; BESUSSO, D et al.European journal of cancer (1990). 2004, Vol 40, Num 8, pp 1275-1281, issn 0959-8049, 7 p.Article